ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,815
-0,37%
Bitcoin
64 181,77
0,29%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Eiger BioPharmaceuticals Inc (EIGR)

  7. Eiger BioPharmaceuticals Inc (EIGR) Actualités

EIGR Eiger BioPharmaceuticals Inc

1,725
0,00 (0,00%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Eiger BioPharmaceuticals Inc EIGR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,725 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,725 1,725
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/4/202417:12GLOBEEiger BioPharmaceuticals Files for Voluntary Chapter 11..
11/3/202421:03EDGAR2Form 8-K - Current report
24/1/202422:59EDGAR2Form 8-K - Current report
18/1/202423:49PRNUSEiger and Partner, AnGes, Receive Approval for Zokinvy®..
08/1/202413:00EDGAR2Form 8-K - Current report
04/1/202414:45EDGAR2Form 8-K - Current report
04/1/202414:00PRNUSEiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse..
11/12/202322:01EDGAR2Form DEF 14A - Other definitive proxy statements
04/12/202312:01EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202322:02EDGAR2Form PRE 14A - Other preliminary proxy statements
24/11/202312:01EDGAR2Form SC 13D - General statement of acquisition of beneficial..
13/11/202322:01EDGAR2Form 8-K - Current report
09/11/202322:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:14EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSEiger BioPharmaceuticals Reports Third Quarter 2023..
03/11/202302:54EDGAR2Form SC 13D/A - General statement of acquisition of..
03/11/202302:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202321:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/10/202322:29EDGAR2Form SC 13D - General statement of acquisition of beneficial..
28/9/202322:54EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/9/202323:17DJNEiger BioPharmaceuticals to Discontinue Chronic Hepatitis..
12/9/202322:42EDGAR2Form 8-K - Current report
12/9/202322:05PRNUSEiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon..
06/9/202303:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202303:35EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202322:05PRNUSEiger BioPharmaceuticals to Present at H.C. Wainwright 25th..
15/8/202312:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/8/202322:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:09EDGAR2Form 8-K - Current report
14/8/202322:05PRNUSEiger BioPharmaceuticals Reports Second Quarter 2023..
28/7/202322:17EDGAR2Form 8-K - Current report
07/7/202322:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/7/202323:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202322:16EDGAR2Form 8-K - Current report
29/6/202314:00PRNUSEiger BioPharmaceuticals to Focus on Metabolic Diseases with..
28/6/202322:05PRNUSEiger BioPharmaceuticals to Host Business Update Call..
11/5/202322:00PRNUSEiger BioPharmaceuticals Reports First Quarter 2023..

Dernières Valeurs Consultées

NASDAQ
EIGR
Eiger BioPharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés